Table 5 Effects of the combined nicotinamide riboside and nicotinamide riboside + resveratrol groups, compared to placebo, on gastrocnemius muscle biopsy outcomes in participants with peripheral artery disease (secondary outcomes)
From: Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
NR alone and NR + resveratrol groups combined | Placebo | Comparison of change between the NR groups and placebo | |||||
|---|---|---|---|---|---|---|---|
Baseline, mean (standard deviation) | Follow-up, mean (standard deviation) | Within group change, LSMeans (standard error) | Baseline, mean (SD) | Follow-up, mean (standard deviation) | Within group change, LSMeans (standard error) | LSMeans (90% CI) P value | |
NAD+ (pmol/mg) | 100.31 (68.33) N = 12 | 115.84 (60.95) N = 12 | 8.70 (17.92) | 92.33 (59.14) N = 5 | 105.71 (46.95) N = 5 | 43.83 (26.15) | −35.13 (−81.20, +∞) P = 0.84 |
Satellite cell (satellite cells/100 fibers) | 24.72 (17.63) N = 11 | 23.50 (12.44) N = 11 | −0.81 (3.32) | 18.30 (11.21) N = 5 | 12.27 (5.66) N = 5 | −11.95 (5.18) | +11.14 (2.16, +∞) P = 0.060 |
Type 1 myofibers (%) | 45.90 (21.73) N = 11 | 44.26 (17.77) N = 11 | −2.88 (3.58) | 56.79 (14.04) N = 5 | 50.34 (16.50) N = 5 | −8.09 (5.75) | +5.21 (−4.47, +∞) P = 0.24 |
